fbpx
WorldWide
Contact
Cholesterol Medication Supplement

Overcoming the side effects of cholesterol medication

For some people, diet and lifestyle changes alone are not enough to combat high cholesterol. High blood cholesterol levels are often genetic and for these individuals, prescription medication such as statins are required.1, 2, 3

Some people might be reluctant to start or continue to use statins due to potential side effects, such as muscle pain and tenderness, cramps, stiffness or muscle weakness.5

The solution to these possible statin side-effects is a simple dosage of one STATIN-GAP capsule per day, which maintains the essential nutrients required for adequate muscle function and strength that may be depleted as a result of cholesterol treatment.

Cholesterol Medication Supplement

For more information on cholesterol, click here

Benefits of statins

STATIN-ASSOCIATED MUSCLE SYMPTOMS1
impact the benefits of statin therapy

BENEFITS2

Reduces the rates of:

  • Major cardiac events
  • Stroke
  • Mortality and all-cause morbidity

Non-adherence/discontinuation from statin therapy due to SAMS (SAMS = statin-associated muscle symptoms) has a marked impact on CVD benefit, resulting in a higher risk of cardiovascular disease and death1

Cholesterol Medication Supplement

Statin-Associated Muscle Symptoms

SAMS = statin-associated muscle symptoms

RISKS OF STATIN THERAPY1

  • Up to 29 % of statin users* experience statin-associated muscle symptoms (SAMS), the most common side effect of statin therapy1
  • Up to 75 % of statin users with SAMS discontinue statin therapy within 2 years1,2
Cholesterol Medication Supplement

Coenzyme Q10 (CoQ10) deficiency

STATIN-ASSOCIATED MUSCLE SYMPTOMS
are potentiated by coenzyme Q10 (CoQ10) deficiency3,4

Vitamin D deficiencies

STATIN-ASSOCIATED MUSCLE SYMPTOMS may be potentiated by vitamin D deficiencies4

Cholesterol Medication Supplement
  • Vitamin D receptors are present in skeletal muscle4
  • Vitamin D is required for muscle strength4
  • Vitamin D deficiency can potentiate SAMS and has been found to be an independent predictor of myalgia4,5

HydroQsorb CoQ10

STATIN-GAP contains HydroQsorb CoQ10 for more efficient cellular uptake6,11

  • Higher efficiency of micellarisation
  • HydroQsorb is incorporated more efficiently at 72 % vs. 52 % for control CoQ1011
  • Micellarisation is a critical step in the absorptive process
  • CoQ10 is hydrophobic and will pass through the intestine unabsorbed if not incorporated into micelles
  • The tissue incorporation of 50 mg HydroQsorb CoQ10 is equivalent
    to that of 200 mg of CoQ1011
  • Higher uptake of micellarised CoQ10 by intestinal cells11
  • HydroQsorb’s cellular uptake is 4.9 times higher vs. CoQ10 control 11
  • The next step in absorption is uptake of micelles by intestinal cells
  • Enhanced uptake of HydroQsorb allows for lower dosages to accomplish the same degree of tissue incorporation
  • The tissue incorporation of 50 mg HydroQsorb CoQ10 is equivalent
    to that of 200 mg of CoQ1011

STATIN-GAP

STATIN-GAP maintains the essential nutrients that may be depleted as a result of the treatment of high cholesterol6

*suggested intake – no specific dietary intake recommendation

Cholesterol Medication Supplement

Dosage & directions for use

Take one (1) capsule daily2

Please note: This is an educational information leaflet only and should not be used for diagnosis. For more information on cholesterol, consult your healthcare professional.

References for introduction:

1. SA Heart and theLipid and Atherosclerosis Society of Southern Africa

2. South African Dyslipidaemia Guideline Consensus Statement Vol 102, No 3, (2012)

3. Health Society of South Africa, Cholesterol Guide, 2014

4. World Health Organisation, Cardiovascular Disease Program, Avoiding Heart Attacks and Strokes, 2005

5.  http://www.adcockgap.co.za/Content/Docs/STATIN_GAP_Product_Info.pdf

Further references:

1. Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society
consensus panel statement on assessment, aetiology and management. Eur Heart J 2015;36(17):1012-1022.

2. Klug EQ, Raal FJ, Marais AD, et al. South African dyslipidaemia guideline consensus statement. A joint statement from the South African Heart Association (SA Heart) and the Lipid and Atherosclerosis Society of Southern Africa (LASSA). SA Fam Pract 2015;57(2): 22-31.

3. Langsjoen PH. The clinical use of HMG CoA-reductase inhibitors (statins) and the associated depletion of the essential co-factor coenzyme Q10; a review of pertinent human and animal data. [cited 2017 March 31]; Available from: https://www.fda.gov/ohrms/dockets/dailys/02/May02/052902/02p-0244-cp00001-02-Exhibit_A-vol1.pdf.

4. Gupta A, Thompson PD. The relationship of vitamin D
deficiency to statin myopathy. Atherosclerosis 2011;215:23-29.

5. Mergenhagen K, Ott M, Heckman K, et al. Low vitamin D as a risk factor for the development of myalgia in patients taking high-dose simvastatin: a retrospective review. Clin Ther 2014;36(5):770-777.

6. Statin-GAP approved package insert, 2017. 7. Coenzyme
Q10 at a glance. Nutrifacts. [cited 2017 March 30]; Available from: http://www.nutri-facts.org/en_US/nutrients/nutraceuticals/coenzyme-q10.html.

8. Coenzyme Q10 (CoQ10): in depth. National Center for Complementary and Integrative Health. US Department of Health and Human Services, National Institutes of Health. [cited 2017 March 30]; Available from: https://nccih.nih.gov/health/supplements/coq10.

9. Ross CA, Taylor CL, Yaktine AL, et al (eds). Dietary Reference Intakes (DRIs): Dietary reference intakes for calcium and vitamin D. Institute of Medicine, National Academy of Sciences, 2011. [cited 2017 Mar 17]; Available from:- https://www.nap.edu/13050.

10. Ferder M, Inserra F, Manucha W. The world pandemic of vitamin D deficiency could possibly be explained by cellular inflammatory response activity induced by the renin angiotensin system. Am J Physiol Cell Physiol 2013;304:C1027-C1039.

11. Craft NE, Failla M. In vitro assessment of coenzyme Q10 bioavailability in three products using Caco-2 cells. Final report, 2006. Craft Technologies Inc.

[easy-social-share buttons=”facebook,twitter,print,mail,whatsapp” morebutton=”2″ morebutton_icon=”dots” style=”icon” fixedwidth_align=”right”]

Brought to you by

Cholesterol Medication Supplement

Related Information